Equipes de recherche - Stabilis 4.0

Dernière mise à jour :
01/04/2025

Equipes de recherche - Quality Evaluation Team, Samsung Bioepis Co

pdf

Japon

Laboratoire pharmaceutique

Quality Evaluation Team, Samsung Bioepis Co

Incheon

Email

sujin8171.park@samsung.com

Bibliographie

Bibliographie

(5)

1

In‑Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M, Jeong H, Yun J, Kim J, Kim S, Lee Y, Park S-J. (sujin8171.park@samsung.com)
Drugs R D - 2023 - ;23,4:363 - 375

2

Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration.
Kaiser P.K, Yun J, Kim S, Kim J, Park S.J. (sujin8171.park@samsung.com)
Ophtalmol Ther - 2023 - ; 12:985–998.

3

Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D, Kim J, Yun J, Park S.J. (sujin8171.park@samsung.com)
Adv Ther - 2020 - ; 37: 4308–4324.

4

Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Yun J, Kim J, Chung J, Hwang S-J, Park S-J. (sujin8171.park@samsung.com)
Adv Ther - 2019 -

5

Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D, Yun J, Hwang S-J, Park SJ. (sujin8171.park@samsung.com)
Adv Ther - 2019 - 36:442–450

Liste des molécules

Molécules étudiées

(5)

		Adalimumab
		Bevacizumab
		Eculizumab
		Ranibizumab
		Trastuzumab

Mentions Légales

BESbswy